Should You Buy Integra LifeSciences Holdings Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings Corporation (IART) occupies a solid middle-ground position with a Quality of Company score of 7.1/10. At the current market price of $15.69, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 4 of 7 CirclFi valuation models project upside for Integra LifeSciences Holdings Corporation (IART) at $15.69 — the model consensus leans bullish, with a Quality Score of 7.1/10 and Value-Trap risk of 29/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Integra LifeSciences Holdings Corporation (IART) in 2026?
What Is the Bull Case vs the Bear Case for Integra LifeSciences Holdings Corporation (IART)?
| Bull case — $45.81 target (+192.0%) | Bear case — $2.05 target (-87.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Integra LifeSciences Holdings Corporation's score of 7.1/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $2.05 (-87.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +33.6% across 4 bullish models from the current price of $15.69. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +278.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $45.81 (+192.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Integra LifeSciences Holdings Corporation and its Medical Devices peers. |
| Industry tailwind: orphan drug designation could provide meaningful support for Integra LifeSciences Holdings Corporation's revenue and margin trajectory in the Medical Devices space. |
How Does IART Compare to Its Medical Devices Peers?
Valuation data pages: LUNG · PHG · SGHT · KIDS · AORT · LNSR · OM · MDAI · GMED · IRMD · PODD
Which Other Stocks Score Like IART on Quality?
Closest companies to IART’s Quality of Company score of 7.1/10, across all industries.
- RBLX — Roblox Corporation (QOC 7.1) · analysis
- BRLT — Brilliant Earth Group, Inc. (QOC 7.1) · analysis
- SHEN — Shenandoah Telecommunications Company (QOC 7.1) · analysis
- GNW — Genworth Financial, Inc. (QOC 7.1) · analysis
- LADR — Ladder Capital Corp (QOC 7.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does IART Appear In?
So Is Integra LifeSciences Holdings Corporation (IART) Worth Buying in 2026?
Integra LifeSciences Holdings Corporation leans positive in our analysis — 4/7 models bullish, median fair value of $20.96 vs. $15.69, QOC 7.1/10. The case is constructive but not overwhelming, and the 3 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Integra LifeSciences Holdings Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About IART Stock?
Should I buy IART stock right now?
Based on CirclFi's multi-model analysis, 4 of 7 models see upside for IART at $15.69. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.1/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Integra LifeSciences Holdings Corporation?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (2139% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does IART compare to its competitors?
Among Medical Devices peers, IART holds a Quality Score of 7.1/10. Comparable companies include LUNG (QOC 7.2), PHG (QOC 7.1), SGHT (QOC 7.2). The relative ranking helps investors identify whether IART offers better fundamental quality than alternatives in the same sector.
Is IART a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. IART's Quality Score of 7.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy IART at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $2.05 to $45.81. At $15.69, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for IART.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad